Neurocrine Biosciences (NASDAQ: NBIX) reported Q3 EPS of $0.97, $0.75 better than the analyst estimate of $0.22. Revenue for the quarter came in at $258.5 million versus the consensus estimate of $283.04 million.

For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.